Kineta to Present Preclinical Data on VISTA Blocking

SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

Related Keywords

San Diego ,California ,United States ,Thierry Guillaudeux ,Jacques Bouchy ,John Mullaly ,Facebook ,Lifesci Advisors ,Monoclonal Antibody Program ,Investor Relations Business Development ,Kineta Inc ,Linkedin ,Nasdaq ,Discovery Development ,Oxford Global Immuno ,Chief Scientific Officer ,Cell Therapies ,Conference Room ,Business Development ,Sci Advisors ,Nasdaq Ka ,Vineta ,Nc ,